Based on lower than expected revenues in the first half of 2017 (H1 2017: approximately EUR 0.5 million), and the continued lack of reimbursement coverage anticipated for the remainder of the year in the U.S. market, Epigenomics now expects 2017 group revenues to be in the range of EUR 1.0 to 1.5 million (previously: about EUR 2.5 million).

Due to lower anticipated revenues and potentially other cost items, adjusted EBITDA (before share-based payment expenses) is expected to be in the range of EUR -12.5 to -14.0 million (previously: EUR -12.0 to -13.5 million).

Epigenomics AG currently expects to publish its 2017 half-year financial report on August 9, 2017.

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.